Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

Engineering a genome-reduced bacterium to eliminate Staphylococcus aureus biofilms in vivo

Bacteria present a promising delivery system for treating human diseases. Here, we engineered the genome-reduced human lung pathogen Mycoplasma pneumoniae as a live biotherapeutic to treat biofilm-associated bacterial infections. This strain has a unique genetic code, which hinders gene transfer to...

Full description

Bibliographic Details
Main Authors: Collantes, M. (Author), Ferrar, T. (Author), Gallo, C. (Author), Garcia-Ramallo, E. (Author), Garrido, V. (Author), Grilló, M.-J (Author), Lluch-Senar, M. (Author), Paetzold, B. (Author), Peñuelas, I. (Author), Piñero-Lambea, C. (Author), Rodriguez-Arce, I. (Author), Serrano, L. (Author), Weber, M. (Author)
Format: Article
Language:English
Published: John Wiley and Sons Inc 2021
Subjects:
animal cell
animal experiment
animal model
animal tissue
antibacterial activity
Anti-Bacterial Agents
antibiofilm activity
antiinfective agent
Article
bacterial genome
bacterial strain
bacterial therapy
bacterial virulence
bactericidal activity
biofilm
Biofilms
biological therapy
controlled study
data analysis software
ex vivo study
female
fluorodeoxyglucose f 18
genetics
human
Humans
in vitro study
in vivo study
in vivo
isoflurane
male
mastitis
microbial products not classified elsewhere
microbial sensitivity test
Microbial Sensitivity Tests
mouse
Mycoplasma
Mycoplasma pneumoniae
nonhuman
promoter region
signal peptide
Staphylococcus aureus
Staphylococcus aureus infection
synthetic biology
virulence factor
Virulence Factors
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items